亚洲知识产权资讯网为知识产权业界提供一个一站式网上交易平台,协助业界发掘知识产权贸易商机,并与环球知识产权业界建立联系。无论你是知识产权拥有者正在出售您的知识产权,或是制造商需要购买技术以提高操作效能,又或是知识产权配套服务供应商,你将会从本网站发掘到有用的知识产权贸易资讯。

Mapping Prostate Cancer from Multi-parametric MRI with Improved Predictive Models

详细技术说明
Diagnosing and Monitoring Prostate Cancer using mpMRI DataA computer-aided diagnostic (CAD) tool, based on a novel predictive model for cancer detection from quantitative multiparametric MRI (mpMRI) data, uses magnetic resonance images to identify key markers of prostate cancer to aid in diagnosing and monitoring prostate cancer. The method, validated on histological prostate cancer tissue, requires the implementation of a multi-parametric MRI study consisting of multiple echo time fast spin echo acquisitions, dynamic contrast enhanced MRI, diffusion weighted imaging at multiple diffusion weightings (b-values), and gradient echo acquisitions at different flip angles. The software automatically processes datasets into a composite biomarker that detects cancerous tissue on a voxel-wise basis and generates pixel-wise maps of disease likelihood, using quantitative measures, to:reduce incidence of false negative biopsies, incorporating instead more active surveillance (i.e., decision to not biopsy)help direct biopsies and improve accuracy of biopsy procedure targets to improve specificity and selectivity for subsequent interventions (e.g., ablation or MR-ultrasound systems)precisely target therapies to reduce comorbiditiesreduce radiologist time needed to analyze each MR scan (thus reducing costs)improve quality of patient careOvercomes PSA, DRE and TRUS LimitationsThe current gold standard for prostate cancer screening, the prostate-specific antigen (PSA) test, results in many false positives and false negatives, and is unable to localize possible tumors or give information on the seriousness of the illness. Current standard for evaluating mpMRI data by way of Prostate Imaging Reporting and Data System are largely subjective using qualitative measures for disease identification and monitoring, and other current diagnostic tests (i.e., digital rectal exams (DRE), and trans-rectal ultrasound (TRUS) guided biopsy), do not provide the information needed to confidently diagnose and manage prostate cancer in an optimized, cost effective way. These limitations result in high numbers of unnecessary, untargeted, painful biopsies (e.g., “random” cores from partitioned sections), and grading based on cores that may not strongly indicate aggressiveness of tumors. This new mpMRI technology overcomes these limitations by way of a unique database of in vivo MRI and correlative pathology, and predictive models (composite biomarkers) for disease detection, grading (and eventually for assessing aggressiveness) on a voxel-by-voxel basis. Essentially, it offers improved models for imaging radiogenomics (i.e., the correlation between cancer imaging features and gene expression) that will improve or change the prostate cancer patient workflow. For example, the process could introduce MR imaging prior to biopsy for detection/grading and/or guidance for biopsy, reduce overtreatment, and improve targeting of therapy (e.g., brachytherapy, external-beam radiotherapy, etc.). Advantages over current approaches include improved performance in terms of overtreatment and under-staging, potential for improved detection, grading, and therapy guidance (which may improve patient outcome and reduce healthcare costs), and voxel-by-voxel quantitative assessment without user intervention.BENEFITS AND FEATURES:Quantitative mpMRI dataIdentifies key markers of prostate cancerAids in diagnosing and monitoring prostate cancerImproves detection/gradingMay reduce number of false negative biopsies; may reduce overtreatmentHelps direct biopsies and improve accuracy of biopsy procedureImproves quality of patient carePrecisely targets therapies (e.g., brachytherapy, external-beam radiotherapy, etc.) to reduce comorbiditiesReduces radiologist time needed to analyze each MR scan (thus reducing costs)Voxel-by-voxel quantitative assessment without user interventionAPPLICATIONS:Prostate cancer diagnosticsAll stages of prostate cancer management and treatmentDirecting biopsies, improving accuracy of biopsyImaging the extent or growth of the cancerConfirming success of surgery or other treatmentsMonitoring prostate cancer without physician interventionComputer-aided cancer detection systemSW as a service for detection/gradingMRI/ultrasound fusion system or MR scannerStandalone computer aided detection software suite or accompaniment to magnetic resonance scannersPhase of Development - Prototype developed
*Abstract
None
国家/地区
美国

欲了解更多信息,请点击 这里
移动设备